Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
6.95%. That's the key number at yesterday's Scheme Meeting for <a href="https://www.smartkarma.com/entities/hangzhou-kangji-medical-instrument-co-ltd" target="_blank" data-smartkarma-citation="entities:28938:1" rel="noopener">Hangzhou Kangji Medical Instrument Co., Ltd. (9997 HK)</a>.
</li>
<li>That's still below the 10% blocking stake. But closer than the bankers and the market was anticipating. </li>
<li>Arguably, the terms were therefore bang on. Last day of trading is today, with payment on the 16th December.</li>
</ul>



6.95%. That's the key number at yesterday's Scheme Meeting for Hangzhou Kangji Medical Instrument Co., Ltd. (9997 HK).

That's still below the 10% blocking stake. But closer than the bankers and the market was anticipating. 
Arguably, the terms were therefore bang on. Last day of trading is today, with payment on the 16th December.


Kangji Medical (9997 HK): A Close Run Thing

<ul>
<li>After suspending shares on the 30th September, SOE-Backed, Chinese property play <a href="https://www.smartkarma.com/entities/minmetals-land-ltd" target="_blank" data-smartkarma-citation="entities:1917:1" rel="noopener">Minmetals Land (230 HK)</a>, has now <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1023/2025102300765.pdf" target="_blank" rel="noopener">announced</a> an Offer, by way of a Scheme buyback, from parent China Minmetals. </li>
<li>The Offer Price of HK$1/share, declared final, is a punchy 185.71% premium to last close. And also a 179% premium over the 30th June 2025 NAV. Optically, looks solid also.</li>
<li>Disinterested shareholders hold 38.12%. They should be happy with terms. This should wrap up (perhaps) late February 2026. </li>
</ul>


After suspending shares on the 30th September, SOE-Backed, Chinese property play Minmetals Land (230 HK), has now announced an Offer, by way of a Scheme buyback, from parent China Minmetals. 
The Offer Price of HK$1/share, declared final, is a punchy 185.71% premium to last close. And also a 179% premium over the 30th June 2025 NAV. Optically, looks solid also.
Disinterested shareholders hold 38.12%. They should be happy with terms. This should wrap up (perhaps) late February 2026. 


Minmetals Land (230 HK): An Offer Premium Of 179% To NAV? Yes Please

<ul>
<li>On the 12th August, <a href="https://www.smartkarma.com/entities/hangzhou-kangji-medical-instrument-co-ltd" target="_blank" data-smartkarma-citation="entities:28938:1" rel="noopener">Hangzhou Kangji Medical (9997 HK)</a> announced an Offer, by way of a Scheme, from a consortium led by TPG and Qatar Investment Authority, together with the founders.</li>
<li>The HK$9.25/share consideration price (declared final), was an lacklustre 9.9% premium to last close. But pitched around a four-year high. </li>
<li>
<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1013/2025101300039.pdf" target="_blank" rel="noopener">The Scheme Document is now out</a>, with a Court Meeting on the 10th November and expected payment around the 16th December - in line with my expectations.</li>
</ul>


On the 12th August, Hangzhou Kangji Medical (9997 HK) announced an Offer, by way of a Scheme, from a consortium led by TPG and Qatar Investment Authority, together with the founders.
The HK$9.25/share consideration price (declared final), was an lacklustre 9.9% premium to last close. But pitched around a four-year high. 

The Scheme Document is now out, with a Court Meeting on the 10th November and expected payment around the 16th December - in line with my expectations.


Kangji Medical (9997 HK): 10th Nov Shareholder Vote on Founders/TPG/QIA's Offer

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hang-seng-bank-ltd" target="_blank" data-smartkarma-citation="entities:24:1" rel="noopener">Hang Seng Bank (11 HK)</a> has announced an Offer from controlling parent (63.3551%), <a href="https://www.smartkarma.com/entities/hsbc-holdings-plc" target="_blank" data-smartkarma-citation="entities:516:1" rel="noopener">HSBC Holdings (5 HK)</a>, by way of a Scheme, in a HK$106bn (US$13.6bn) deal. </li>
<li>The Scheme Consideration is HK$155/share, a 30.3% premium to last close. The price is final. A "third interim dividend" will be added. Optically, the price is bang on.</li>
<li>The long stop for conditions is the 30th September 2026. I think this transaction can be wrapped up in around five months. </li>
</ul>



Hang Seng Bank (11 HK) has announced an Offer from controlling parent (63.3551%), HSBC Holdings (5 HK), by way of a Scheme, in a HK$106bn (US$13.6bn) deal. 
The Scheme Consideration is HK$155/share, a 30.3% premium to last close. The price is final. A "third interim dividend" will be added. Optically, the price is bang on.
The long stop for conditions is the 30th September 2026. I think this transaction can be wrapped up in around five months. 


HSBC (5 HK)'s Clean Offer for Hang Seng (11 HK)'s Minorities

<ul>
<li>With the pre-cons squared away as per the <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0903/2025090302242.pdf" target="_blank" rel="noopener">3rd September announcement</a>, the key risk to <a href="https://www.smartkarma.com/entities/hangzhou-kangji-medical-instrument-co-ltd" target="_blank" data-smartkarma-citation="entities:28938:1" rel="noopener">Hangzhou Kangji Medical Instrument (9997 HK)</a>'s Offer is the Scheme vote. </li>
<li>The HK$9.25/share consideration price (declared final), was an uninspiring 9.9% premium to last close. But pitched around a four-year high. And peers are down 10% on average since the Offer.</li>
<li>A perusal of the s329 investigative reports provides a significantly clearer picture on who holds what.</li>
</ul>


With the pre-cons squared away as per the 3rd September announcement, the key risk to Hangzhou Kangji Medical Instrument (9997 HK)'s Offer is the Scheme vote. 
The HK$9.25/share consideration price (declared final), was an uninspiring 9.9% premium to last close. But pitched around a four-year high. And peers are down 10% on average since the Offer.
A perusal of the s329 investigative reports provides a significantly clearer picture on who holds what.


Kangji Medical (9997 HK): A Closer Look At The Shareholder Register

Hong Kong

Dickson Concepts (International) Limited is an investment holding company primarily engaged in the retail and wholesale of luxury goods, including fashion, accessories, watches, jewelry, cosmetics, and leather goods. The company also has a segment for securities investment and provides ancillary services like interior design and property investment. Founded in 1980, it is headquartered in Tsim Sha Tsui, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dickson Concepts (113 HK)

Kangji Medical (9997 HK): A Close Run Thing

Done & dusted. But closer than expected. This will trade at or close to terms. Cash out or wait for payment. If not in, perhaps run a ruler over...

David Blennerhassett

Minmetals Land (230 HK): An Offer Premium Of 179% To NAV? Yes Please

Clean deal. If small-cap illiquid arbs are your bent get involved here. I'd pay up to HK$0.95/share, assuming end of February 2026 payment.

David Blennerhassett

Kangji Medical (9997 HK): 10th Nov Shareholder Vote on Founders/TPG/QIA's Offer

I expect this Offer gets up. I'd pay up to ~HK$9.00/share for a ~15% annualised return. If you have the risk bandwidth for HK arbs, get involved.

David Blennerhassett

HSBC (5 HK)'s Clean Offer for Hang Seng (11 HK)'s Minorities

Assuming five months to wrap this, pay up to HK$148/share for a 15% annualised return. Including the third interim dividend of HK$1.20/share.

David Blennerhassett

Kangji Medical (9997 HK): A Closer Look At The Shareholder Register

I expect this Offer gets up. Assuming payment shortly before Xmas, I'd pay up to ~HK$8.95/share for a 15% annualised return. If you have the risk...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)